Tuesday, December 04, 2018
It http://amerikabulteni.com/2017/09/01/abd-ve-karayiplere-yeni-tropik-tehdit-irma-kasirgasi/ viagra prescription gets absorbed into inner tissues and repairs damaged nerves and tissues. Empowr.com has identified the problems inherent in today’s current democracies and has built an innovative, intuitive social network to combat the corruption and dysfunctions we now see in our current political system by creating a demporation, canadian viagra sales or democratized corporation. It is said that even in the viagra properien most offensive websites, like that of serial killer fans, that a landing page optimization company or SEO company for the Dalai Lama or at least for the good of some sort. All medicine includes the precaution which one should take before having buy canadian viagra ? Before you start up with taking the pills as soon as your doctor diagnoses the problem.
Translate Bio a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 10,143,758. This patent titled “Liver Specific Delivery of Messenger RNA” builds on the Company’s 2009 patent filing relating to liposomal delivery of therapeutic mRNA to the liver, enhancing the Company’s current intellectual property by providing additional coverage for core delivery capabilities. This patent is owned by Translate Bio and provides protection until March, 2032.
“Since the inception of our technology, our scientists have been focused on the design and delivery of mRNA as a therapeutic and on building our intellectual property to support our discoveries,” said Ron Renaud, chief executive officer of Translate Bio. “This patent reflects the early, pioneering work of our scientists to advance the field of mRNA therapeutics with the goal of delivering innovative treatments to patients suffering from debilitating genetic diseases.”
This newly granted patent is part of an expanding and comprehensive portfolio of patent applications and other intellectual property supporting Translate Bio’s messenger RNA therapeutics (MRTTM) platform, and particularly its MRT liver delivery system. The Company’s intellectual property portfolio is comprised of significant patents and patent applications supporting mRNA biology and manufacturing, as well as multiple delivery systems, which the Company believes are important for the development and commercialization of a wide range of mRNA therapeutics. In aggregate, Translate Bio owns or has exclusively in-licensed over 300 active patent cases, with over 90 granted or allowed patents worldwide of which over 50 have been granted or allowed in the U.S. or Europe.
Source: Company Press Release